Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis

Modern Rheumatology

Volumn 25, Issue 6, 2015, Pages 913-918

  Chen, Ming Han ^a,b   Chen, Hung An ^c   Chen, Wei Sheng ^a,b   Chen, Ming Huang ^a   Tsai, Chang Youh ^a,b   Chou, Chung Tei ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Ankylosing spondylitis; Bone morphogenetic protein; Inflammation; Interleukin 1 ; Tumor necrosis factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; C REACTIVE PROTEIN; CYTOKINE; HLA B27 ANTIGEN; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; BMP2 PROTEIN, HUMAN; BMP4 PROTEIN, HUMAN; BMP7 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; LOW BACK PAIN; MALE; MIDDLE AGED; MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINAL SCORE; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACROILIITIS; DISEASE COURSE; DRUG EFFECTS; GENETICS; METABOLISM; MONONUCLEAR CELL; RADIOGRAPHY; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 7; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84946824589     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1029221     Document Type: Article

References (36)

1. Lories RJ, Luyten FP. Bone morphogenetic protein signaling and arthritis. Cytokine Growth Factor Rev. 2009;20(5-6):467-73.
2. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am. 2002;84-A(6):1032-44.
3. Wozney JM. Overview of bone morphogenetic proteins. Spine. 2002;27(16 Suppl 1):S2-8.
4. Sailor LZ, Hewick RM, Morris EA. Recombinant human bone morphogenetic protein-2 maintains the articular chondrocyte phenotype in long-term culture. J Orthop Res. 1996;14(6):937-45.
5. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage. 1998;6(5):306-17.
6. Cheng SL, Lou J, Wright NM, Lai CF, Avioli LV, Riew KD. In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int. 2001;68(2):87-94.
7. Khan MA, van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am. 1990;16:551-79.
8. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford). 2005;44(12):1483-91.
9. Braem K, Luyten FP, Lories RJ. Blocking p38 signalling inhibits chondrogenesis in vitro but not ankylosis in a model of ankylosing spondylitis in vivo. Ann Rheum Dis. 2012;71(5):722-8.
10. Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006;54(6):1736-46.
11. Lories RJ, Luyten FP. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005;16(3):287-98.
12. Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2010;11:232. doi:10.1186/1471-2474-11-232.
13. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27(3):2662-73.
14. Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther. 2007;9(2):207.
15. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115(6):1571-9.
16. Chen HA, Chen CH, Lin YJ, Chen PC, Chen WS, Lu CL, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol. 2010;37(10):2126-32.
17. Khan MA. HLA-B27 and its pathogenic role. J Clin Rheumatol. 2008;14(1):50-2.
18. Lories RJ, Derese I, Ceuppens JL, Luyten FP. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003;48(10):2807-18.
19. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am. 2003;85-A Suppl 3:59-66.
20. Fukui N, Ikeda Y, Ohnuki T, Hikita A, Tanaka S, Yamane S, et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem. 2006;281(37):27229-41.
21. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005;111(8):2364-72.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8.
23. Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, van de Tempel H, van der Heijde D. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol. 2004;31(1):125-32.
24. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910-5.
25. Altman RD. The classification of osteoarthritis. J Rheumatol Suppl. 1995;22(Suppl 43):42-3.
26. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127-9.
27. van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis. 2008;67(9):1218-21.
28. Kellgren JH, Lawrence JS. Radiologic assessment of osteoarthritis. Ann Rheum Dis. 1957;16(4):494-502.
29. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11(2):221. doi:10.1186/ar2642.
30. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 2007;56(2):489-97.
31. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324-31.
32. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007;46(9):1450-3.
33. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710-5.
34. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645-54.
35. Park MC, Park YB, Lee SK. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol. 2008;37(3):200-4.
36. Wang YF, Teng MM, Chang CY, Wu HT, Wang ST. Imaging manifestations of spinal fractures in ankylosing spondylitis. AJNR Am J Neuroradiol. 2005;26(8):2067-76.